1. Name and Address of Reporting Person

Andres Juan
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139

2. Issuer Name and Ticker or Trading Symbol

Moderna, Inc. [ MRNA ]

5. Relationship of Reporting Person(s) to Issuer

X Officer (give title below)
Director
10% Owner
Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)

09/01/2021

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person
Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

09/03/2021

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 4)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>09/01/2021</td>
<td></td>
<td>M(1) 5,000 A</td>
<td>5,000 D</td>
<td>X Direct (D)</td>
<td>X Direct (D)</td>
</tr>
<tr>
<td>Common Stock</td>
<td>09/01/2021</td>
<td></td>
<td>V(1) 5,000 D</td>
<td>$361.82 0</td>
<td>X Direct (D)</td>
<td>X Direct (D)</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$12.21</td>
<td>09/01/2021</td>
<td>M(1)</td>
<td>5,000 (2)</td>
<td>08/29/2027 Common Stock 5,000</td>
<td>$0 299,822</td>
<td>D Direct (D)</td>
<td>X Direct (D)</td>
<td>X Direct (D)</td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
2. This option is fully vested and exercisable.

Remarks:
Chief Technical Operations and Quality Officer

As/ Brian Sandstrom, as Attorney-in-Fact 09/03/2021

Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.